Open AccessClinical and Pharmacological Considerations for Concomitant Administration of Posaconazole and Isavuconazole with Letermovir
Author(s) -
Jean Terrier,
Marie-Céline Zanella,
Stavroula MasouridiLevrat,
Ilona Kronig,
Yves Chalandon,
Nathalie Vernaz,
Christian van Delden,
Genovefa A. Papanicolaou,
Dionysios Neofytos
Publication year - 2021
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.00274-21
Subject(s) - posaconazole , concomitant , medicine , pharmacology , antifungal , amphotericin b , dermatology
We sought in this case-control retrospective study to compare posaconazole and isavuconazole (PCZ and IVC, respectively) plasma trough concentration ( C trough ) levels in high-risk allogeneic hematopoietic cell transplant (HCT) recipients who received letermovir (LET) or not. PCZ/IVC C trough levels were not found to be significantly different between cases and controls, as they were 1.31 mg/liter (median) (interquartile range [IQR], 0.90) versus 1.36 mg/liter (IQR, 1.16) ( P = 0.31) and 3.20 mg/liter (IQR, 2.40) versus 2.35 mg/liter (IQR, 1.50) ( P = 0.17), respectively. In conclusion, we observed PCZ/IVC C trough levels within the expected range and no significant effect of LET coadministration.